Design
Review
Authors
Loading...
Does not support practice changes in RAS inhibition; leaves open therapeutic targeting of ACE2/angiotensin-(1-7) in cardiovascular and renal disease.
Key points are not available for this paper at this time.
Carlos M. Ferrario (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: